当前位置： SCI文献检索 > EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE期刊下所有文献 > Phenoconversion of CYP2D6 by inhibitors modifies aripiprazole exposure.

Phenoconversion of CYP2D6 by inhibitors modifies aripiprazole exposure.

Abstract：

:The efficacy of aripiprazole therapy and the risk of adverse reactions are influenced by substantial inter-individual variability in aripiprazole metabolizing capacity. In vitro studies assigned the potential role in aripiprazole metabolism to CYP2D6 and CYP3A enzymes; therefore, the association between the steady-state aripiprazole plasma concentrations and patients' CYP2D6 and CYP3A statuses (CYP2D6, CYP3A4, and CYP3A5 genotypes, and CYP3A4 expression) and/or co-medication with CYP function modifying medications has been investigated in 93 psychiatric patients on stable aripiprazole therapy. The patients' CYP2D6 genotype had a major effect on aripiprazole plasma concentrations, whereas contribution of CYP3A genotypes and CYP3A4 expression to aripiprazole clearance were considered to be minor or negligible. The role of CYP3A4 expression in aripiprazole metabolism did not predominate even in the patients with nonfunctional CYP2D6 alleles. Furthermore, dehydroaripiprazole exposure was also CYP2D6 genotype-dependent. Dehydroaripiprazole concentrations were comparable with aripiprazole levels in patients with functional CYP2D6 alleles, and 35% or 22% of aripiprazole concentrations in patients with one or two non-functional CYP2D6 alleles, respectively. The concomitant intake of CYP2D6 inhibitors, risperidone, metoprolol, or propranolol was found to increase aripiprazole concentrations in patients with at least one wild-type CYP2D6*1 allele. Risperidone and 9-hydroxy-risperidone inhibited both dehydrogenation and hydroxylation of aripiprazole, whereas metoprolol and propranolol blocked merely the formation of the active dehydroaripiprazole metabolite, switching towards the inactivation pathways. Patients' CYP2D6 genotype and co-medication with CYP2D6 inhibitors can be considered to be the major determinants of aripiprazole pharmacokinetics. Taking into account CYP2D6 genotype and co-medication with CYP2D6 inhibitors may improve the outcomes of aripiprazole therapy.

journal_name

Eur Arch Psychiatry Clin Neurosci

journal_title

European archives of psychiatry and clinical neuroscience

authors

Kiss Á,Menus Á,Tóth K,Déri M,Sirok D,Gabri E,Belic A,Csukly G,Bitter I,Monostory K

doi

10.1007/s00406-018-0975-2

subject

Has Abstract

pub_date

2020-02-01 00:00:00

pages

71-82

issue

eissn

0940-1334

issn

1433-8491

pii

10.1007/s00406-018-0975-2

journal_volume

270

pub_type

杂志文章

在线工具

Phenoconversion of CYP2D6 by inhibitors modifies aripiprazole exposure.